IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:	Dickerson *et al.*
Application No.:	10/530,985
Confirmation No.	2557
Filed:	April 12, 2005
Art Unit:	1624
Examiner:	Jeffrey Murray
For:	PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS
Customer No.:	23347

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This paper is submitted in response to the Office Action mailed January 8, 2008. Early examination of the application on the merits is earnestly solicited.

The Examiner has found lack of unity of invention in the claims and has required the election of an invention selected from Groups I to LXIII. Applicants elect to prosecute the claims of Group VI, *i.e.* claims 1-7 and 16-18, wherein R^1 is phenyl and D is N. In the accompanying preliminary amendment, Applicants have amended the claims such that all the pending claims (i.e. claims 1, 4-7, 16, 26, and 27) are directed to the elected invention.

Should a preliminary species election for the purposes of examination be required, Applicants elect the compound of Example 62, i.e. 4-[2-(4-methoxyphenyl)pyrazolo[1,5-b]pyridazin-3-yl]-N-phenylpyrimidin-2-amine.

Applicants expressly reserve the right to file divisional applications or take such other measures deemed necessary to protect the inventions represented by the unelected subject matter.

Should the Examiner have any further questions or comments regarding the prosecution of this case, it is respectfully requested that the Examiner telephone the undersigned attorney so that further examination of this application may be expedited.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

Kathryn L. Coulter

Kathryn L. Coulter
Registration No. 45,889
Attorney for Applicant

Date: 2/6/2008

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1467
Facsimile: (919) 483-7988